S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Endocyte, Inc. and a Lead Plaintiff Deadline of August 25, 2014 -- ECYT|
|Endocyte Reports Second Quarter Financial Results and Provides Clinical Update|
|ENDOCYTE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $500,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Endocyte, Inc. -- ECYT|
|SHAREHOLDER ALERT: Brower Piven Encourages Investors With Losses Over $100,000 in Endocyte, Inc. to Contact the Firm Before the Lead Plaintiff Deadline in Class Action Lawsuit -- ECYT|
|Phase 2b TARGET Trial Results Show Improved Survival in Adenocarcinoma Non-Small Cell Lung Cancer Patients Treated With Endocyte's Vintafolide|
|SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Endocyte, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of August 25, 2014 -- ECYT|
|UPCOMING DEADLINE: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Endocyte, Inc. and a Lead Plaintiff Deadline of August 25, 2014 -- ECYT|
|Endocyte Reports Third Quarter Financial Results and Provides Clinical Update|
|Endocyte Announces Presentations at the 248th American Chemical Society National Meeting & Exposition|
|Endocyte Scientific Team Selected to Receive 2015 George and Christine Sosnovsky Award for Cancer Research|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
Click above to view more mutual fund data and stats for ecyt - Endocyte Inc.